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Abstract: A mathematical model is developed to further examine the dynamic interaction of
uninfected T cells with Human Immunodeficiency Virus (HIV) mutations. We study how the
dynamics are affected by immune response to infected cells under intermittent antiretroviral
therapy. Our goal is to analyze the SMART (Strategies for Management of Anti-Retroviral
Therapy) study outcomes and based on that try to identify possible causes of its failure. We
mathematically describe the HIV infection and perform numerical simulation to approach the
course of the disease. Preliminary results suggest that the scheduling of follow-up visits and
working range of CD4+ T cells count used during the SMART study could explain the observed
adverse outcomes in that trial.
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1. INTRODUCTION
HIV infection takes place when the glycoprotein gp120 on
surface of HIV fits the protein marker cluster designation 4
(CD4) on the surface of most immune cells. Cells with this
marker are referred to as being CD4 plus (CD4+) or helper
T cells, Annah (2006). HIV recognizes CD4+, attaches to
it and to a chemokine co-receptor (CXCR4 or CCR5) to
facilitate to enter into the host cell by fusion between the
HIV membrane and the host immune cell. Since 1996 when
the use of protease inhibitors (PI) were acknowledged as
effective against HIV, new antiretroviral drugs have been
developed as part of an ongoing effort to try to control
or prevent the replication of HIV, Panel (2006). The
combination of three or more different antiretroviral drugs,
commonly referred to as Highly Active Antiretroviral
Therapy (HAART) has proven to bring enormous benefits
for most HIV positive patients.
HAART slows remarkably the replication of HIV in the
blood and in many cases reduces the amount of active virus
(viral load) to undetectable levels. The International AIDS
(Acquired Immune Deficiency Syndrome) Society of USA
recommends therapy for all symptomatic patients and for
asymptomatic patients with CD4+ below 200 cells/mm3.
Further, therapy should be considered and discussed with
patients whose CD4+ are 200-350. Therapy should typi-
cally be deferred for asymptomatic patients with CD4+
> 350, Brian (1998). Although several studies to deter-
mine the appropriate moment to start therapy have been
proposed, Jeffrey et al. (2003), infected patients are in
most cases advised to commence HAART even before
they develop symptoms of AIDS. The fact that HAART
is an aggressive treatment has caused concerns related to
consequences of its long term use. This motived alternative
treatment strategies as discussed in next section.
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2. THE SMART STUDY
The risk of significant toxicity and side effects have been a
motivation for researchers to investigate new strategies to
deal with HIV infection. As one of the options to HAART,
the so called Structured Treatment Interruptions (STI)
was developed with view to relieve HAART medication-
related toxicity, to make HIVmore sensitive to drugs (since
continuous therapy may cause drug resistance) and to re-
stimulate the immune system by allowing a controlled rise
in the viral load. In this context, SMART was proposed
as a large international trial designed to determine which
of two distinct HIV treatment strategies yields a better
clinical outcome over the long term.
The SMART study was supposed to run for over 9 years,
but it was prematurely stopped after 2 years due to a
significantly greater risk of opportunistic infections (OIs)
or deaths in those who were assigned to receive interrupted
therapy. SMART trial set out to recruit 6000 patients, all
with CD4+ count ≥ 350 cells/mm3 who were randomized
in two groups: First, continuous drug therapy or Viral
Suppression group (VS), aimed at suppression of the viral
load to undetectable levels, irrespective of the CD4+. Sec-
ond, episodic therapy or Drug Conservation group (DC),
designed to stop HAART when patients’ CD4+ reached
350, and resumed when counts fell back down to 250
or less. Before randomization, participants’ antiretroviral
therapy history and medical history were obtained. Follow-
up visits were scheduled at 1 month and 2 months, every
2 months thereafter for the 1st year, and every 4 months
in the second and subsequent years, SMARTgroup (2006).
Other trials based on CD4+ cell count-guided therapy are:
i) Staccato study, Ananworanich et al. (2003). ii) Trivacan
study, Danel et al. (2006), iii) BASTA trial, Maggiolo et al.
(2003) and iv) Short-cycle, Cardiello et al. (2005). These
trials involved a number of patients considered too small
to allow for the reliable assessment of effects of treatment
interruption on clinical outcomes.
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2.1 Clinical outcomes
The SMART study enrolled 5472 patients (2720 assigned
to DC and 2752 to VS) from 318 research sites in 33
countries. The patients had been followed up for a median
of 14 months, during which there had been 164 recorded
instances of disease progression, defined as death, or the
development of a serious AIDS-related condition or a
serious complication. Table 1 presents the relationship
between adverse outcomes, proximal CD4+ and viral load
levels, see Sadr and Neaton (2006). The primary finding
revealed a 2.5 fold increased risk of disease progression or
death in DC group as compared with the VS group.
Lundgren (2006) presented an analysis to determine why
patients in the DC group, who spent very little time below
200 cells/mm3 presented very bad results. OIs and death
occurred more often among patients with lower CD4+ and
higher viral loads. It was found that combining both CD4+
T cell count and viral load was more predictive of the risk
than either marker alone, demonstrating that the risk of
OIs or death is reflected by both lower CD4+ and higher
viral loads. However, it should be noted that CD4+ and
viral load markers did not explain all of the risk increase
and there were other factors — yet to be identified — that
also played some role in increasing the risk of OIs or death
when interrupting therapy.
El-Sadr (2006) examined the risk factors that might help
explain the elevated OIs and death in the DC group. They
showed that the overall hazard ratio was 2.6, which means
that participants in the DC were more than twice as likely
to experience OIs or death. Among patients with viral load
levels of 400 copies/ml or less, the rate of OIs or death was
3.2 in the DC arm, compared with 0.8 in the VS group.
However, among patients with HIV RNA levels higher
than 400 copies/ml, there was no significant difference.
2.2 Conclusions from SMART study group
Treatment interruption guided by the CD4+ count, sig-
nificantly increased the risk of OIs or death, as compared
with continuous therapy, largely as a consequence of low-
ering the CD4+ and increasing the viral load. Treatment
interruptions should be avoided unless motivated by some
significant need, such as serious antiretroviral toxicity. The
conclusion from Lundgren (2006) is that there must be a
“missing link” that would explain the unexpected high
risk of adverse outcomes in patients undergoing treat-
ment interruption, some “impairment of immune function
not reflected in peripheral blood CD4+”. El-Sadr (2006)
concluded that across a range of baseline demographic
characteristics, the findings were similar. The only baseline
characteristic that had a different outcome was baseline
viremia, i.e., the risk of treatment interruption was most
pronounced in patients who entered the study with a viral
load below 400 copies/ml, which suggests that viremic
patients, whether ON or OFF therapy, carry a similar
risk of adverse events. According to them, the rates of
adverse outcomes were higher in DC group across all
analyzed subgroup, and none appeared to benefit from
treatment interruption. However, some groups did expe-
rience particularly inferior outcomes. According to Cohn
(2006) the incidence of both serious and non-serious events
was greater in the DC arm than in the VS arm.
Table 1. Adverse outcomes - SMARTgroup (2006)
VS DC
Time on treatment 93% 33%
Median of interruptions − 3
Disease progression 47 (1.5%) 117 (3.7%)
Patients more likely to die 0.9% 1.7%
Serious progression of disease 0.1% 0.6 %
Risk of serious complications 1.4% 2.1 %
Person year of follow-up
% of patients
72.3% of
3701
28.8% of
3666
HIV RNA level 400 400
Therapy during follow-up time 94% 33%
Fatal or non-fatal OIs 47 120
Median proximal CD4+ count 540 343
Follow-up time with CD4<350 7% 32%
Overall median viral load (logs) 2.6 4.0
Types and severity of clinical events - Cohn (2006)
Clinical events occurred 20 70
Patients in OFF therapy (%) 30 57
Serious events with CD4+< 350 0 9
Non serious events with CD4<350 7 34
Serious events with CD4+=350 4 6
Non serious events with CD4=350 11 26
However, among patients with proximal CD4+ of 350, the
proportion of serious events was similar in both groups. A
substudy to examine quality of life among 1225 SMART
participants is presented by Burman (2006) concluded that
episodic use of therapy did not improve quality of life of
the patients. In treatment interruption, however, physical
functioning, general health perception and energy scores
worsened among patients in the DC group compared to the
VS group. The different studies on SMART trials suggest
that the type of treatment provides little if any benefit
and considerable risk of both minor and life-threatening
adverse events.
Finally, the SMART study has provided an answer to its
primary goal, demonstrating that CD4+-guided treatment
interruptions were inferior to continuous treatment within
the study. Therefore, on January 10, 2006, the board
recommended stopping enrollment in the SMART trial
because of a safety risk in the DC group and because
it appeared to be very unlikely that the superiority of
the drug conservation treatment would be shown. All
patients were advised to restart continuous treatment,
SMARTgroup (2006).
3. MATHEMATICAL MODELING SMART
A Preliminary analysis of the SMART’s results have
suggested that the increased progression risk in patients
undergoing treatment interruption may be explained in
part by their lower CD4+ over the course of the study.
Despite this explanatory verification, we seek a more
detailed analysis by using mathematical modelling, that
may lead to a clearer explanation. We use dynamic analysis
from a control theoretic point of view, looking at the
interaction of HIV infection and its treatment as a process
continuously evolving over time. This is done by describing
CD4+ and viral load and using well established ordinary
differential equation models for the dynamics of HIV
infection. We also include the infected cells produced when
free virus infects target CD4+.
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Also, many studies have proven that the immune system
can provide selection pressure for or against viral diversity,
Nowak and Charles (1996). Therefore, we include in the
model a simplified description of the genetic mutation of
HIV. Ferreira and Middleton (2008) studied the dynamic
properties of viral mutations of a model with a single
point mutation in wild type (HIV-1). In their analysis of
all possible equilibria and local stability properties, they
proved that generically, there exists a locally unstable fixed
point corresponding to an uninfected state and a locally
stable equilibrium corresponding to the infected steady
state. Ferreira et al. (2009) made a generalization of their
technique to systems of m viral variants. They concluded
that despite viral diversity, there exists two different valid
equilibria: i) Uninfected state (locally unstable equilib-
rium) and ii) Infected state (m possible equilibria), where
only one (corresponding to the fittest strain) is locally
stable.
Since SMART was designed to examine the effects of
intermittent treatment, notably the impact of therapy on
the immunologic system, we include the immune response
to infection. Such consideration provides information to
assess the role of Cytotoxic T lymphocytes (CTL) and
how they are affected by viral diversity in the following
model extended from Kwon (2007).
T˙ = sT − dTT − T
m∑
i=1
ri
T˙ ∗1 = (1− µ) r1 + µr2 − dT∗T
∗
1 − δT
∗
1Z1
T˙ ∗i =µri−1+ (1-2µ) ri + µri+1 − dT∗T
∗
i -δT
∗
i Zi, i=2,. . . ,m-1
T˙ ∗m = µrm−1 + (1− µ) rm − dT∗T
∗
m − δT
∗
mZm
V˙i = piT
∗
i − dV Vi, i = 1, . . . ,m
Z˙i = κZiT
∗
i − dzZi, i = 1, . . . ,m
(1)
where r ∈ Rm = [r1, r2, . . . , rm]
T .
(1) describes the interaction between the replicating virus
and host cells, as well as the immune system and the
HIV mutations. T ∗1 ,. . ., T
∗
m denote each cell infected with
a different virus strain (or mutant), V1, . . . , Vm that are
produced from uninfected target cells T (CD4+) at infec-
tion rates ri = TβiVi, i = 1, . . . ,m. Therefore, there are
m viral variants in (1). Zi denotes the magnitude of the
specific CTL produced in response to presence of T ∗i which
decay at rate dT∗T
∗
i
. Clearance of infected cells is modelled
by CTL at rate δT ∗
i
Zi. The term κZiT
∗
i
represents the
proliferation of CTL in response to antigen. CTL decay at
rate dzZi. Parameter µ denotes the probability of mutation
to resistant mutant during reverse transcription (RT) of
viral RNA into proviral DNA. T cells are produced by
thymus gland at constant, sT . Their interaction with free
virus produce T ∗
i
at rate βi, which in turn produce new
virus particles at rate pi. Parameters βi and pi are selected
to satisfy β1 ≥ β2 ≥ · · · ≥ βm and p1 ≥ p2 ≥ · · · ≥ pm
respectively. T , Vi and T
∗
i
die at rates dT , dT∗ and dV
respectively. κ denotes the magnitude of Zi against Vi.
According to Nowak and Charles (1996), κ is defined as
the growth rate of specific CTL after encountering T ∗
i
.
According to Wodarz (2001), helper-dependent response
can be modeled in greater details by distinguishing be-
tween CTLp (precursors) and CTLe (effectors). This is
because help seems to be required more for the expansion
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Fig. 1. Profile of CD4, CTL proliferation and infected cells
.
of CTLp population and not for the differentiation into
effectors. Hence, if help becomes limiting, the rate of differ-
entiation is greater than the rate of expansion, resulting in
the extinction of the helper-dependent CTL response, see
Doherty (1993). This does not apply to helper-independent
response which can be captured by the single variable Zi.
Annah et al. (2007) applied control theoretical concepts to
study STI schedules with equal ON/OFF periods. They
concluded that failure of most STI clinical trials could
be attributed to failure to re-establish two conditions: i)
whether or not the OFF therapy period is short enough
and ii) whether or not ON therapy period is long enough
to re-establish the conditions before the interruption.
However, they do not consider explicitly the CTL and HIV
mutation. Furthermore, their clinical trial was based on a
much smaller cohort of 36 patients.
We studied the relationship between HIV and the immune
system during the natural course of infection, i.e., not
taking into account any therapy. It was observed that
HIV escapes from CTL response due to genetic mutation.
As the immune system responds to HIV-1 (non-mutated
virus) a first mutant arises and becomes dominant. This
mutant is then recognized by CTL and again the immune
system reacts by eliminating this mutated virus. A new
HIV variation arises and once again the immunologic
system acts to clear it. These alterations occurring in the
virus structure are characteristics during the acute HIV
infection when the amount of HIV in the blood is very
high. At this short stage of the disease the infected cells
producing new viruses are almost completely destroyed
either by the immune system (figure 1) or by natural
death. Consequently, after the initial peak the viral load
drops to very low levels causing a stabilization in CD4+,
leading the patient to clinical latency (figure 1), a phase
of the disease in which the virus may remain dormant for
several years and produce few or no new copies of HIV.
4. EXPLANATIONS FOR SMART FAILURE
In some cases patients present long-term nonprogressor
status, i.e., HIV positive patients with relatively high
CD4+ and therefore high levels of CTL, Autran and
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Fig. 2. Control system block diagram.
Garcelain (2000). However, because the immune system
can not completely eradicates the virus in the long term,
then most infected patients are expected to develop AIDS.
A treatment strategy to reduce and prevent mutant virus
particles and infected cells as well as to rise the uninfected
CD4+ T cells count is necessary.When the SMART study
began, data indicated that the risk of AIDS was low among
patients who had never received antiretroviral therapy and
among those who had received it but who also had CD4+
counts of more than 200 cells/mm3, Phair et al. (2002).
Consequently, the SMART committee chose to use a CD4+
T count threshold of 250 cells per cubic millimeter for
initiation (or reinitiation) of antiretroviral therapy in the
DC group, SMARTgroup (2006). The CD4+ T cell count
thresholds for stopping and starting antiretroviral therapy
were chosen also on the basis of reported associations
between CD4+ counts and the risks of OIs and death,
Bethesda (2006).
In control engineering terms, this corresponds to using
a simplified “ relay ” switching scheme, also known as
ON-OFF control and common in thermostatic systems.
See Bennett (1993) for details. Such control systems have
proven very effective in controlling low order (1 or two
states) systems, with simple dynamics, provided rapid
measurements (ideally continuous) are used. In the case
of the SMART study, there are two major potential
shortcomings of the “control” (i.e., STI regime) design.
Firstly, the dynamics of HIV infection are quite high or-
der, exhibiting non-linear and complex damped oscillatory
responses. Such systems are unsuitable for simple relay
control systems. Secondly, the measurement regime is,
for good clinical reasons, not very frequent. However, the
sampling rate should be faster than the system dynamics,
which in the case of HIV, shows substantial dynamic
behavior over intervals of days or weeks.
We model the input control, ui(k), corresponding to drug
administrated by replacing βi with (1− ηuRTi)βi and pi
with (1− ηuPIi) pi, where uRTidenotes the effect of RT
enzyme which acts to block new infections, uPIi denotes
the effect of PI which causes the infected T cells to produce
non-infectious virus and η < 1 is the maximum drug
efficacy. Figure 2 shows diagrammatic representation of
the relationship among the basic elements of the feedback
control system. Each sampled data is compared with the
working range defined for the CD4+ block. ui(k) ∈ [0, 1]
means that ui is only allowed to assume OFF or ON, corre-
sponding to stop or (re)initiate treatment respectively, de-
pending on the difference, e(k), and the scheduling defined
for the follow-up visits. (1) is represented by patient model
block and the noise corresponds to undesirable input signal
(lack of accuracy in measurements, human error etc).
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Fig. 3. Infected cells and viral load during OFF therapy.
In figure 3 the immune system reacts to increasing of
infected cells that springs back as consequence of inter-
mittent rebound of HIV during treatment interruption.
This simulation is intended to highlight that even in pa-
tients who have no easily detectable HIV in their blood,
HIV does rapidly rebound to high levels if the drugs are
discontinued. These observations are in agreement with
clinical findings presented by Kalams et al. (1999) who
studied the interaction between the host cellular immune
response and HIV-1 infection before and after the start of
HAART. Their results suggest that CTL numbers decline
rapidly when viral load is reduced by drug therapy. Ac-
cording to Chun et al. (1997), there exists an HIV-1 latent
reservoir in infected patients despite prolonged treatment
with HAART. Another possibility is that HIV may stay
hidden in CD4+ T cells more susceptible to infection
before initiation of therapy. Palmer et al. (2008) suggest
that low-level persistent viremia appears to arise from at
least two cell compartments, one in which viral production
decays over time and a second in which viral production
remains stable for at least 7 years. In figure 3 the treatment
is able to keep viral load at very low levels throughout ON
therapy. However, as drugs do not completely clear HIV,
then during OFF therapy more copies of HIV are produced
leading to a higher viral load.
One of the problems of this intermittent treatment is
reflected in the profile of CD4+ with monthly follow-up
visits for the 1st year of treatment and different initial
conditions, see figure 4. Notice that although the period
under therapy is able to re-establish healthy cells (CD4+ >
350), because of the long time till the next follow-up visits
(every 30 days) there is an important decay of healthy cells
before the therapy is reinitiated. Furthermore, even after
re-commencement of treatment, the CD4+ count declines
further before recovering to a safe number. Therefore, the
T cell count temporarily drops well below the critical level
(200 cells/mm3). This suggests a much worst result if we
consider the follow-up visits scheduled every 4 months as
proposed for the 2nd and subsequent years of the trial.
Numerical simulations were performed with the following
parameter values from Jeffrey and Xia (2002), Nowak and
Charles (1996): sT = 10mm
−3day−1, dT = 0.02day
−1,
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Fig. 4. Profile of CD4+ with monthly follow-up visits.
β1 = 2.4e
−6 ≥ β2 ≥ · · · ≥ βm, p1 = 100 ≥ p2 ≥ · · · ≥ pm,
dT∗ = 0.24day
−1, dV = 0.24day
−1, κ = 0.05, dz = 0.05,
δ = 1, µ = 0.0001.
5. CONCLUSIONS FROM THEORETICAL STUDIES
Dynamics from (1) in figure 3 qualitatively shows that
during ON therapy the CTL response declines as the
viral load drops to very low levels, in agreement with
Wodarz (2001) who verified that at the initial stage of
therapy, the degree of immune impairment is reduced while
levels of virus load are still sufficiently high to induce an
initial expansion of the helper-dependent CTL response.
However, viral load subsequently drops to very low levels,
insufficient to maintain the CTL response. This could be
due to scheduled follow-up visits that contributes notably
to decline CD4+ to below 250 and consequently may
expose patients to OIs. By making a relation between these
conclusions and the results from clinical data of Lundgren
(2006) in which the authors wondered why patients under
SMART did so poorly with CD4+< 200 cells/mm3 for
a short time, the following issues are open for further
investigations:
i) Recal from table 1 that patients spent 32% of their
follow-up time with CD4+ < 350 cells/mm3 and that in
figure 4, patients are prone to serious events because of
exposition to critical levels of CD4+. It would be therefore
of interest to consider STI strategies with briefer OFF
therapy intervals. This could be achieved either by more
frequent diagnostic visits or by replacing “OFF” therapy
by a short term (eg., 1 week) interruption followed by
resumption of therapy.
ii) SMART study recommended that treatment interrup-
tions should be avoided unless motivated by some sig-
nificant need (serious antiretroviral toxicity). Further, if
an interruption occurs, patients should be closely moni-
tored and therapy preferentially restarted at higher CD4+
(about 350) than those used in the SMART. This clearly
highlights that, effectively, the follow-up time originally
scheduled made the patients more likely to experience OIs
due to low CD4+. In addition, the treatment design may
have given better clinical outcomes had it been aimed at
keeping the minimum predicted CD4+ count above 250.
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Fig. 5. Guided CD4+ therapy combined with viral load.
This of course requires simple formulae of software capable
of short term extrapolation of sampled CD4+ levels.
iii) Sadr and Neaton (2006) suggest that the decision to
(re)commence and stop therapy based on a combination of
both CD4+ T cell count and viral load is more predictive
of the risk than either marker alone, demonstrating that
the risk of OIs or death is reflected by both lower CD4+
and higher viral loads.
Figure 5 combines an every 10 days of follow-up evaluation
assuming both guided viral load (60-400 copies/ml) and
guided CD4+ (250-350 cells/mm3) therapy. Notice that
CD4+ T cell count does not drop to the critical level (200
cells/mm3) during the 1st year. This alternative scheme
provides better immunologic control to prevent OIs while
at the same time limit exposure to HAART with its
attendant side effects. Our conjecture is based on the fact
that the onset of AIDS occurs, on average, about 5 to 10
years after infection. This is supported by Richard (2008)
who observed that the beginning of AIDS has is correlated
with the diminution of the number of CD4+ but the major
loss of T cells occurs late in HIV infection. Therefore,
from a hypothetical point of view, CD4+ marker used in
SMART study was not the most appropriate predictor of
serious OIs.
The mathematical description developed for the disease
progression has emphasized the important role played by
immune response during the first stages of the disease
(primary infection and asymptomatic phase). Our results
suggest that the long follow-up visits (monthly) does
not allow to preserve a satisfactory immune response in
patients during withdrawal of therapy.
We are currently working on a more realistic approxima-
tion to describe the shift from clinical latency to symp-
tomatic infection and subsequent progression from HIV to
AIDS. The new approach will be also used as platform for
the development of control strategies based on the body’s
own defences to drive patient’s state to LTNP.
(Chapter head:)*
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